Roche has announced its financial results for the 2016 business year, during which it achieved a group sales total of 50.58 billion Swiss francs (40.67 billion pounds).
This represents a five percent year-on-year increase in terms of Swiss francs or four percent on a constant exchange rate basis. Pharmaceutical sales growth was driven mainly by the cancer medicines Perjeta and Herceptin, as well as Actemra/RoActemra, while its diagnostics division performance was benefited from strong demand for immunodiagnostic solutions.
“Roche has met all of its financial goals for the year during 2016.“
During the year, the company introduced four new medicines to market, including its first cancer immunotherapy Tecentriq, while a new immunodiagnostic instrument called Cobas e 801 was also launched.
For 2017, Roche expects sales to grow at a low to mid-single digit rate in constant exchange terms, while core earnings per share are targeted to grow broadly in line with sales.
Severin Schwan, Roche's chief executive officer, said: "I am pleased that we have again reached all our financial targets while our product portfolio has made significant progress."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical